Smith+Nephew Helps Personalize Robotically-Enabled Surgery With AI-Powered Planning Software And Data Visualization Platform

 Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today introduces two key products that close the feedback loop for its robotics and digital surgery portfolio – Personalized Planning

 Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today introduces two key products that close the feedback loop for its robotics and digital surgery portfolio – Personalized Planning powered by AI and RI.INSIGHTS Data Visualization Platform.

These solutions transform data into contextual intelligence by enabling surgeons to see how pre-operative surgical plans and intra-operative decision-making link to post-operative outcomes.

RI.KNEE ROBOTICS™ v2.0 – Personalized Planning powered by AI

Smith+Nephew’s CORI™ Surgical System expands its capability in knee replacement with Personalized Planning powered by AI, guided by RI.INSIGHTS data. This new addition enables the surgeon to set the initial implant placement within the total knee arthroplasty procedure based on AI-guided reference values and the surgeon’s planning preferences for specific implants and patient-specific deformities.

“Advanced analytics combined with the CORI Surgical System will offer a new dimension in joint arthroplasty. It will allow for true personalization when performing joint replacement procedures,” said Dr. Thorsten Seyler of Duke University.

This AI-powered enhancement enables surgeons to customize planning to both their preferences and the patient’s anatomy at the time of surgery.

Total
0
Shares
Related Posts
Read More

Why Cimpress Stock Is Up After Earnings

Cimpress beat estimated earnings by 72.58%, reporting quarterly earnings of $2.14 per shares versus the analyst consensus estimate of $1.24. The company reported quarterly sales of $921.36 million which beat the analyst consensus estimate of $892.1 million by 3.28% and represents a 9% increase over sales of $845.20 million the same period last year.

CMPR

Read More

Reported Sunday, BioNTech Three-Year Phase 1 Follow-Up Data For mRNA-based Individualized Immunotherapy Candidate Shows Persistence Of Immune Response And Delayed Tumor Recurrence In Some Patients With Resected Pancreatic Cancer

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to

BNTX